Skip to main content
637 search results for:

Combination therapy 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-09-2022 | ESMO 2022 | Conference coverage | Article

    MONARCH 3: OS ‘numerically favors’ abemaciclib combination therapy

    Investigator Matthew Goetz (Mayo Clinic, Rochester, Minnesota, USA) presented the latest update from the phase 3 trial at the ESMO Congress 2022 in Paris, France, reminding delegates that the progression-free survival (PFS) analysis previously demonstrated a significant benefit with the abemaciclib combination, but OS data were not mature at that time.

  2. 02-07-2020 | FDA | News | Article
    approvalsWatch

    FDA approves outpatient combination HER2-positive breast cancer therapy

    Pertuzumab, trastuzumab, and hyaluronidase-zzxf may be given as a neoadjuvant treatment for locally advanced, inflammatory or early-stage breast cancer, or as an adjuvant therapy for patients with early disease and a high risk of recurrence.

  3. 20-10-2023 | Prostate cancer | News | Article

    Enzalutamide use supported for biochemically recurrent prostate cancer

    Shore and colleagues note that “[n]o substantial difference was noted in the time to first deterioration of [Functional Assessment of Cancer Therapy–Prostate] total scores in the combination group or the monotherapy group as compared with the leuprolide-alone group.”

  4. 26-07-2017 | Teaser

    Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer

    Advances in cancer treatment have been driven by the development of targeted therapies and therapies that stimulate antitumor immunity. This review discusses the immune-modulating effects of targeted therapies and how they may synergize with immunotherapy. Summary points Targeted therapies inhibit tumor-intrinsic drivers of growth and can elicit significant but transient clinical responses. Checkpoint inhibitors are immunotherapies that relieve suppressive signals acting on host T cells to unleash antitumor T cell activity. They can elicit durable responses in subsets of patients across multiple tumor types. In addition to the inhibition of oncogenic signaling pathways and tumor-associated angiogenesis, targeted therapies can enhance aspects of cancer immunity, such as tumor antigenicity, T cell trafficking, or T cell infiltration into tumors. This provides a rationale for combining them with checkpoint inhibitors or other cancer immunotherapies that may lead to synergistic efficacy. Considerations for the clinical development of combinations of targeted therapies and immunotherapies include optimizing dosing regimens, minimizing treatment related toxicities, and selecting appropriate biomarkers and endpoints to assess efficacy. Hughes PE, Caenepeel S, & Wu LC. Trends Immunol  2016; 37: 462–4-76. doi: 10.1016/j.it.2016.04.010

  5. 06-10-2023 | Prostate cancer | News | Article

    Add-on SBRT improves outcomes of men with oligometastatic CRPC

    All participants received abiraterone at a daily dose of 1000 mg alongside prednisone 5 mg twice a day as well as concomitant androgen deprivation therapy, with those randomly assigned to the experimental arm additionally receiving at least 100 Gy SBRT across all sites of metastatic disease.

  6. 22-09-2023 | KRAS inhibitors | News | Article

    Novel KRAS inhibitor elicits ‘durable responses’ in KRAS G12C mutation-positive tumors

    Participants had disease that was resistant or intolerant to at least one available standard therapy or disease for which an investigational clinical trial is considered standard of care.

  7. 23-05-2018 | Renal cell carcinoma | Article

    The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma

    Barata PC et al.  Br J Cancer  2018. doi:10.1038/s41416-018-0104-z

  8. 08-09-2023 | Non-small-cell lung cancer | News | Article

    Add-on tumor treating fields boost metastatic NSCLC survival

    Supplementing standard systemic therapy with tumor treating fields prolongs the overall survival of previously treated patients with metastatic NSCLC.

  9. 26-07-2017 | Teaser

    Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy

    It is not completely clear how best to incorporate molecularly targeted and immune-targeted therapies into combination regimens in cancer treatment. This review discusses these combination approaches and their potential for cancer management. Summary points Though monotherapy regimens for cancer have yielded some success, there are significant limitations with regard to response rates and duration of therapy. Given the growing success of immunotherapy regimens across cancer types, there is significant interest in combining immunotherapeutic approaches with standard and novel agents (ie, chemotherapy, radiotherapy, targeted therapy) to exploit potential synergy. The premise behind this is that several treatments may make a tumor more immunogenic, thus enhancing the effects of immunotherapy when these strategies are given in combination. Rational design of these combination strategies requires a deep understanding of the effects of each therapy alone (and in combination) on host anti-tumor immunity. The influence of chemotherapy, radiation therapy, and molecularly targeted therapy on the host anti-tumor immune response and the host anti-host response (ie, autoimmune toxicity) must be taken into consideration when designing immunotherapy-based combination regimens. Wargo JA, Reuben A, Cooper ZA, Oh KS, & Sullivan RJ.  Semin Oncol  2015;42: 601–616. doi: 10.1053/j.seminoncol.2015.05.007

  10. 01-07-2016 | Treatment | Article

    Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer

    Advances in cancer treatment have been driven by the development of targeted therapies and therapies that stimulate antitumor immunity. This review discusses the immune-modulating effects of targeted therapies and how they may synergize with immunotherapy. Hughes PE, Caenepeel S, & Wu LC. Trends Immunol  2016; 37: 462–4-76. doi: 10.1016/j.it.2016.04.010

  11. 04-11-2017 | Breast cancer | Article

    Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2− advanced breast cancer: a review

    Freedman RA & Tolaney SM. Breast Cancer Res Treat 2017. doi:10.1007/s10549-017-4560-6

  12. 08-08-2023 | Renal cell carcinoma | News | Article

    Potential of pembrolizumab plus lenvatinib for non-clear-cell RCC shown

    The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

  13. 30-06-2023 | Prostate cancer | News | Article

    First-line talazoparib plus enzalutamide supported for mCRPC

    The talazoparib plus enzalutamide combination was also associated with significantly longer median time to PSA progression (26.7 vs 17.5 months; HR=0.72), time to initiation of cytotoxic therapy (unreached vs unreached; HR=0.49), and time to progression or death on the first subsequent anticancer therapy (36.4 vs 35.3 months; HR=0.77) than placebo plus enzalutamide.

  14. 01-08-2015 | Treatment | Article

    Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy

    It is not completely clear how best to incorporate molecularly targeted and immune-targeted therapies into combination regimens in cancer treatment. This review discusses these combination approaches and their potential for cancer management. Wargo JA, Reuben A, Cooper ZA, Oh KS, & Sullivan RJ.  Semin Oncol  2015;42: 601–616. doi: 10.1053/j.seminoncol.2015.05.007

  15. 05-06-2023 | Breast cancer | Conference coverage | Article
    ASCO 2023

    Adjuvant ribociclib reduces recurrence risk in early breast cancer

    Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

  16. 05-05-2023 | Breast cancer | News | Article

    DESTINY-Breast02 supports T-DXd as ‘preferred’ regimen after progression on T-DM1

    They add that the study confirms “the favourable benefit–risk profile” of T-DXd in this patient population, as previously reported in the single-arm, phase 2 DESTINY-Breast01 trial, and supports “this drug as the preferred therapy for patients who received trastuzumab emtansine.”

  17. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    A summary of the key trial publications on the use of PD-1 pathway and CTLA-4 inhibitors alone or in combination in the second-line or later treatment of locally advanced and metastatic urothelial carcinoma. This independent article was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  18. 08-03-2023 | EMA | News | Article
    approvalsWatch

    EMA backs niraparib–abiraterone dual-action tablet for mCRPC

    The decision by the Committee for Medicinal Products for Human Use states that the dual-action therapy is indicated for adult patients with mCRPC carrying germline and/or somatic BRCA1 or BRCA2 mutations who are not able to receive chemotherapy.

  19. 14-03-2023 | EMA | News | Article
    approvalsWatch

    EMA recommends extension to cemiplimab indication

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has endorsed the adoption of a new indication for cemiplimab, to treat patients with PD-L1-positive, advanced non-small-cell lung cancer (NSCLC) in combination with platinum-based chemotherapy.

  20. 24-02-2023 | Renal cell carcinoma | News | Article

    CheckMate 914: Adjuvant nivolumab–ipilimumab not supported for high-risk RCC

    Regarding safety, the incidence of treatment-related adverse events (TRAEs) of grade 3 or 4 was higher in the combination than placebo arm, at 28% versus 2%, as was the rate of discontinuation due to TRAEs of any grade, at 29% versus 1%.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.